Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yosuke Togashi

Showing results (81-90 of 156) with videos related to

Pageof 16
Sort By:
Blood Advances|September 2, 2020
The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphomaJoji Nagasaki, Yosuke Togashi, Takeaki Sugawara, et al.
Springerplus|February 13, 2015
Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancerKazuko Sakai, Azusa Yoneshige, Akihiko Ito, et al.
Clinical Transplantation|May 28, 2026
Risk Factors for Waiting List Mortality in Lung Transplant Candidates With Post-Hematopoietic Stem Cell Transplantation Non-Infectious Pulmonary ComplicationsHisao Higo, Satoru Senoo, Satoko Makimoto, et al.
Cancer Science|November 4, 2018
Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancerSatomi Watanabe, Hidetoshi Hayashi, Koji Haratani, et al.
Lung Cancer (Amsterdam, Netherlands)|February 8, 2025
Efficacy of amivantamab, a bi-specific antibody targeting EGFR and MET, in ALK-rearranged non-small-cell lung cancer cell linesTatsuya Nishi, Ayako Morita, Naofumi Hara, et al.
JTO Clinical and Research Reports|October 6, 2023
Immunologic Significance of CD80/CD86 or Major Histocompatibility Complex-II Expression in Thymic Epithelial TumorsHideki Ikeda, Joji Nagasaki, Daiki Shimizu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 18, 2010
Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysisYosuke Togashi, Katsuhiro Masago, Masahide Fukudo, et al.
Oncotarget|June 17, 2014
Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS productionYosuke Togashi, Tokuzo Arao, Hiroaki Kato, et al.
Molecular Cancer Therapeutics|December 4, 2016
Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung CancerYoshihisa Kobayashi, Koichi Azuma, Hiroki Nagai, et al.
International Journal of Oncology|June 18, 2015
EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibitionTakuro Mizukami, Yosuke Togashi, Shunsuke Sogabe, et al.
Pageof 16

Showing results (81-90 of 156) with videos related to

Sort By:
Pageof 16
Blood Advances|September 2, 2020
The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphomaJoji Nagasaki, Yosuke Togashi, Takeaki Sugawara, et al.
Springerplus|February 13, 2015
Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancerKazuko Sakai, Azusa Yoneshige, Akihiko Ito, et al.
Clinical Transplantation|May 28, 2026
Risk Factors for Waiting List Mortality in Lung Transplant Candidates With Post-Hematopoietic Stem Cell Transplantation Non-Infectious Pulmonary ComplicationsHisao Higo, Satoru Senoo, Satoko Makimoto, et al.
Cancer Science|November 4, 2018
Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancerSatomi Watanabe, Hidetoshi Hayashi, Koji Haratani, et al.
Lung Cancer (Amsterdam, Netherlands)|February 8, 2025
Efficacy of amivantamab, a bi-specific antibody targeting EGFR and MET, in ALK-rearranged non-small-cell lung cancer cell linesTatsuya Nishi, Ayako Morita, Naofumi Hara, et al.
JTO Clinical and Research Reports|October 6, 2023
Immunologic Significance of CD80/CD86 or Major Histocompatibility Complex-II Expression in Thymic Epithelial TumorsHideki Ikeda, Joji Nagasaki, Daiki Shimizu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 18, 2010
Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysisYosuke Togashi, Katsuhiro Masago, Masahide Fukudo, et al.
Oncotarget|June 17, 2014
Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS productionYosuke Togashi, Tokuzo Arao, Hiroaki Kato, et al.
Molecular Cancer Therapeutics|December 4, 2016
Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung CancerYoshihisa Kobayashi, Koichi Azuma, Hiroki Nagai, et al.
International Journal of Oncology|June 18, 2015
EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibitionTakuro Mizukami, Yosuke Togashi, Shunsuke Sogabe, et al.
Pageof 16